Key Points
- Heartflow CEO John Farquhar sold 38,900 shares for about $2.17 million at an average price of $55.74, reducing his direct stake by 13.37% to 251,983 shares. The sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards.
- Heartflow reported quarterly revenue of $64.08 million, up 47.7% year over year, and a loss of $0.07 per share—better than the $0.22 loss analysts expected.
- Analysts’ average rating is “Moderate Buy”, with a consensus price target of $48.62; shares recently opened at $55.80, near the reported 52-week high of $60.56.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John Farquhar sold 38,900 shares of Heartflow stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $55.74, for a total value of $2,168,286.00. Following the transaction, the chief executive officer directly owned 251,983 shares of the company's stock, valued at $14,045,532.42. The trade was a 13.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John C.M. Farquhar also recently made the following trade(s):
- On Monday, October 12th, John Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $49.57, for a total value of $1,928,273.00.
- On Friday, September 11th, John Farquhar sold 3,890 shares of Heartflow stock. The stock was sold at an average price of $50.00, for a total transaction of $194,500.00.
- On Thursday, September 10th, John Farquhar sold 35,010 shares of Heartflow stock. The stock was sold at an average price of $46.42, for a total transaction of $1,625,164.20.
- On Friday, August 21st, John Farquhar sold 27,230 shares of Heartflow stock. The shares were sold at an average price of $50.00, for a total transaction of $1,361,500.00.
- On Tuesday, August 18th, John Farquhar sold 32,676 shares of Heartflow stock. The shares were sold at an average price of $45.00, for a total transaction of $1,470,420.00.
- On Friday, August 14th, John Farquhar sold 15,560 shares of Heartflow stock. The stock was sold at an average price of $39.06, for a total transaction of $607,773.60.
Heartflow Stock Down 1.5%
Heartflow stock opened at $55.80 on Wednesday. The firm's 50 day simple moving average is $51.56 and its 200 day simple moving average is $34.87. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $60.56.
Heartflow (NASDAQ:HTFL - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The firm had revenue of $64.08 million for the quarter. The firm's quarterly revenue was up 47.7% compared to the same quarter last year. As a group, analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current year.
Institutional Trading of Heartflow
Several institutional investors and hedge funds have recently made changes to their positions in HTFL. GAMMA Investing LLC increased its stake in Heartflow by 75.1% in the third quarter. GAMMA Investing LLC now owns 641 shares of the company's stock valued at $32,000 after acquiring an additional 275 shares during the last quarter. Allworth Financial LP lifted its stake in Heartflow by 116.4% during the third quarter. Allworth Financial LP now owns 1,145 shares of the company's stock worth $57,000 after purchasing an additional 616 shares during the last quarter. IFP Advisors Inc lifted its stake in Heartflow by 844.7% during the third quarter. IFP Advisors Inc now owns 803 shares of the company's stock worth $40,000 after purchasing an additional 718 shares during the last quarter. Strs Ohio lifted its stake in Heartflow by 35.3% during the first quarter. Strs Ohio now owns 4,600 shares of the company's stock worth $112,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Heartflow in the 2nd quarter worth about $53,000.
Analyst Ratings Changes
A number of equities analysts have weighed in on the company. Canaccord Genuity Group upped their target price on Heartflow from $45.00 to $56.00 and gave the stock a "buy" rating in a research note on Tuesday, September 22nd. Wall Street Zen downgraded Heartflow from a "buy" rating to a "hold" rating in a research report on Saturday. Robert W. Baird set a $45.00 price target on Heartflow in a research report on Friday, August 14th. Morgan Stanley boosted their price objective on Heartflow from $35.00 to $40.00 and gave the stock an "equal weight" rating in a report on Friday, August 14th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Heartflow from $35.00 to $45.00 and gave the stock an "overweight" rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $48.62.
Read Our Latest Report on HTFL
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient's coronary arteries and provide information that can support diagnosis and treatment planning. The company's offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
